Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 M versus AMINOSYN II 4 25 W ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINOSYN II 3 5 M versus AMINOSYN II 4 25 W ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10 IN PLASTIC CONTAINER.
AMINOSYN II 3.5% M vs AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential and nonessential amino acids for protein synthesis, serving as substrates for anabolic processes in parenteral nutrition.
Aminogen (amino acids) provide substrate for protein synthesis; dextrose provides caloric energy; electrolytes maintain acid-base and fluid balance; phosphate is essential for cellular metabolism and buffering.
Intravenous infusion of 1.2 to 2.2 g amino acids per kg per day, adjusted to meet metabolic and nutritional requirements. Typical adult dose: initial infusion rate of 50 mL/hour, increasing to 125 mL/hour (4.4 g amino acids per hour) based on tolerance. Not for direct peripheral administration without supplementation of electrolytes and/or dextrose.
Intravenous infusion; typical adult dose: 1-1.5 g amino acids/kg/day, with dextrose providing 10% final concentration. Adjusted to meet protein and caloric needs.
None Documented
None Documented
The terminal elimination half-life of amino acids from the infusion mixture is not uniformly defined; however, individual amino acids have half-lives ranging from 10 to 30 minutes. For the mixture, the effective half-life is clinically considered to be approximately 1-2 hours, reflecting rapid metabolic clearance. In renal impairment, the half-life may be prolonged due to reduced urea clearance.
Amino acids have a terminal elimination half-life of approximately 1.5–2 hours in healthy adults, reflecting rapid metabolic clearance. In renal impairment, half-life may be prolonged due to accumulation of nitrogenous waste.
Aminosyn II 3.5% M is a crystalline amino acid solution. Amino acids are primarily eliminated by metabolic utilization for protein synthesis and energy production. Excess amino acids undergo deamination, with nitrogen excreted as urea in urine via renal route. Fecal and biliary excretion are negligible. Approximately 80-90% of infused nitrogen is recovered as urea in urine in patients with normal renal function.
The components of AMINOSYN II (amino acids) and dextrose are primarily metabolized; excess nitrogen is excreted renally as urea. Dextrose is completely oxidized. Electrolytes are excreted mainly renally. Biliary/fecal elimination is negligible for amino acids and dextrose (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution